Woodline Partners LP Sells 74,567 Shares of Boston Scientific Corporation $BSX

Key Points

• Woodline Partners LP sold 74,567 shares of Boston Scientific, reducing its stake by 15.5% in the first quarter, leaving them with holdings valued at approximately $41.15 million.
• Boston Scientific reported a quarterly earnings of $0.75 EPS, surpassing analysts' expectations, with a revenue of $5.06 billion, marking a year-over-year increase of 22.8%.
• Analyst ratings show a strong consensus on Boston Scientific, with three analysts rating it a Strong Buy and a majority giving it a Buy rating, indicating positive market sentiment.

Woodline Partners LP trimmed its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 15.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 407,886 shares of the medical equipment provider's stock after selling 74,567 shares during the quarter. Woodline Partners LP's holdings in Boston Scientific were worth $41,148,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. HM Payson & Co. grew its stake in shares of Boston Scientific by 1.4% during the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock valued at $694,000 after purchasing an additional 98 shares during the last quarter. Park Square Financial Group LLC grew its stake in shares of Boston Scientific by 5.2% during the first quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock valued at $208,000 after purchasing an additional 103 shares during the last quarter. HHM Wealth Advisors LLC grew its stake in shares of Boston Scientific by 13.2% during the first quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider's stock valued at $89,000 after purchasing an additional 103 shares during the last quarter. Rise Advisors LLC grew its stake in shares of Boston Scientific by 13.9% during the first quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider's stock valued at $85,000 after purchasing an additional 103 shares during the last quarter. Finally, Forum Financial Management LP lifted its holdings in Boston Scientific by 0.8% in the first quarter. Forum Financial Management LP now owns 13,448 shares of the medical equipment provider's stock valued at $1,357,000 after buying an additional 112 shares during the period. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Performance

Shares of BSX traded down $1.39 during midday trading on Monday, reaching $101.32. The stock had a trading volume of 3,022,817 shares, compared to its average volume of 7,461,969. The firm has a 50 day simple moving average of $104.86 and a 200-day simple moving average of $102.27. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50. The firm has a market cap of $150.13 billion, a PE ratio of 60.28, a P/E/G ratio of 2.47 and a beta of 0.65. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company's quarterly revenue was up 22.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Robert W. Baird increased their price objective on shares of Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Raymond James Financial increased their price objective on shares of Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a report on Thursday, July 24th. Leerink Partnrs upgraded shares of Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $121.00 target price on shares of Boston Scientific in a report on Thursday. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $118.04.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director owned 18,479 shares of the company's stock, valued at $1,959,328.37. This trade represents a 17.79% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 174,214 shares of company stock worth $18,397,457. 0.50% of the stock is currently owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.